Outcome of Board Meeting

August 10, 2026 BSE Limited, National Stock Exchange of India Limited, Floor 25, P. J. Towers Dalal Exchange Plaza, Bandra-Kurla Complex, Street, Fort Bandra (E), Mumbai - 400 001 Mumbai - 400051 Scrip Code: 530019 Symbol: JUBLPHARMA Sub.: Outcome of the Board Meeting held on August 10, 2026 Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") Dear Sirs, Pursuant to the provisions of Regulation 33 read with Regulation 30 and other applicable provisions of the Listing Regulations, we wish to inform you that the Board of Directors of the Company has, at its meeting held today i.e. on Monday, August 10, 2026, at 05:30 p.m. that concluded at 07:05 p.m., has inter alia approved the unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026. Pursuant to the applicable provisions of the Listing Regulations, we enclose the following: a) The unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30, 2026; b) Limited Review Report on the unaudited Financial Results (Standalone and Consolidated) for the said quarter. The above mentioned documents will be simultaneously posted on the Company's website at www.jubilantpharmova.com. You are requested to kindly take the same on record. Thanking you, Yours faithfully, For Jubilant Pharmova Limited Naresh Kapoor Company Secretary Encl: as above Walker Chandiok &_Co LLP Walker Chandiok & Co LLP Unit No. 02, Second Floor, BPTP Capital City, Plot No - 2B, Sector-94, Naida, Gautam Buddha Nagar -201301 Uttar Pradesh. India T +91 120 485 5999 F +91 120 485 5902 Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Jubilant Pharmova Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) To the Board of Directors of Jubilant Pharmova Limited 1. We have reviewed the accompanying statement of standalone unaudited financial results {'the Statement') of Jubilant Pharmova Limited ('the Company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'). 2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. Ch81'Tered Accounlanls WalKer Chandiok 8 Co LLP is regislered with limited liability with identification number AAC ·2085 and has Offices lri AhmedaD.ad, B84"'1!Jakl~. Chandi(}arh. Chermai. Dehl"OOun. Goai, Gurugram. Hy,dt3rii,ad, Indore, Kochi, l<:alkata, Mumbai, its registered office at L--41, Connaught Circus, New Delhi, Noida and Puna Outer Circle. New Delhi, 110001, India Walker Chandiok &_Co LLP 4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. For Walker Chandiok &.,,G, LLP Chartered Accounta9ts' Firm Registratio~N6: 00i1·076N/N500013 _ if,, -;__QLLP..,.~.k, cs: '"<,~ Ashish Gupta o., Partner ~.i,,71/M ,.ci' Membership No:. 504662 UDIN: 26504662TMHFBZ6243 Place: Noida Date: 10 August 2026 Jubilant Pharmova Limited Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.) CIN:L24116UP1978PLC004624 Website: www.jubilantpharmova.com, Email: investors@jubl.com, Tel: +91-5924-267437 Statement of Standalone Unaudited Financial Results for the Quarter ended 30 June 2026 ('fin million) Quarter Ended Year Ended 30June 31 March 30June 31 March Sr. No. Particulars 2026 2026 2025 2026 (Unaudited) (Audited) (Unaudited) (Audited) CONTINUING OPERATIONS 1 Revenue from operations a) Sales/Income from operations 671 703 595 2,634 b) Other operating income 1 Total revenue from operations 671 703 595 2,635 2 Other income 1 5 7 24 3 Total income (1+2) 672 708 602 2,659 4 Expenses a) Employee benefits expense 283 248 232 1,038 b) Finance costs 9 9 30 73 c) Depreciation and amortisation expense 14 13 15 60 d) Other expenses 268 310 260 1,109 Total expenses 574 580 537 2,280 5 Profit before exceptional items and tax (3-4) 98 128 65 379 6 Exceptional items 87 87 7 Profit before tax (5-6) 98 41 65 292 8 Tax expense -Current tax 20 2 12 46 -Deferred tax charge/(credit) 5 (533) 12 47 Total tax expense/(benefit) 25 (531) 24 93 9 Profit for the period from continuing operations (7-8) 73 572 41 199 DISCONTINUED OPERATIONS Profit from discontinued operations 26 43 Tax expense/(benefit) of discontinued operations 9 (390) 10 Profit after tax from discontinued operations 17 433 11 Profit for the period (9+10) 73 572 58 632 12 Other comprehensive income/(loss) A} In respect of continuing operations a) Items that will not be reclassified to profit or loss 1 1 (1) b) Income tax relating to items that will not be reclassified to profit or loss (2) (1) Sub total 1 (1) (1) (1) B} In respect of discontinued operations a) Items that will not be reclassified to profit or loss (12) b) Income tax relating to items that will not be reclassified to profit or loss 4 Sub total (8) Other comprehensive income/{loss) for the period 1 (1) (1) (9) 13 Total comprehensive income for the period {11+12) 74 571 57 623 14 Earnings per share of"' 1 each (not annualized for the quarters} (for continuing operations) Basic(,) 0.46 3.59 0.26 1.25 Diluted(,) 0.46 3.59 0.26 1.25 Earnings per share of"' 1 each (not annualized for the quarters) {for discontinued operations) Basic(,) 0.10 2.72 Diluted(,) 0.10 2.72 Earnings per share of"' 1 each (not annualized for the quarters) (for continuing and discontinued operations) Basic(,) 0.46 3.59 0.36 3.97 Diluted(,) 0.46 3.59 0.36 3.97 15 PaidHup equity share capital (face value per share"' 1) 159 159 159 159 16 Reserves excluding revaluation reserves (other equity) 22,964 See accompanying notes to the Standalone Unaudited Financial Results Jubilant Pharmova Limited Notes to the Standalone Unaudited Financial Results 1. These standalone unaudited financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 and other accounting princip [Showing first 8,000 characters — download PDF for full document]